1. Home
  2. SPRO vs PGZ Comparison

SPRO vs PGZ Comparison

Compare SPRO & PGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Logo Principal Real Estate Income Fund of Beneficial Interest

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$9.10

Market Cap

66.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
PGZ
Founded
2013
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
73.4M
66.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
PGZ
Price
$1.24
$9.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 711.7K
17.8K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
★ 12.26%
EPS Growth
★ 111.81
N/A
EPS
★ N/A
N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$1.08
$9.08
52 Week High
$3.08
$10.60

Technical Indicators

Market Signals
Indicator
SPRO
PGZ
Relative Strength Index (RSI) 50.69 14.26
Support Level $1.10 N/A
Resistance Level $1.27 $10.50
Average True Range (ATR) 0.06 0.12
MACD 0.02 -0.03
Stochastic Oscillator 38.24 3.21

Price Performance

Historical Comparison
SPRO
PGZ

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.

Share on Social Networks: